Friday, 19 Oct 2018

You are here

Advantages of Intravenous Pulse Cyclophosphamide in ANCA-associated Vasculitis

Researchers from the Nottingham University Hospitals have analyzed the efficacy and safety of  oral (PO) and intravenous (IV)  cyclophosphamide (CTX) in ANCA-associated vasculitis (AAV) patients and demonstrated a trend for fewer relapses, better 1 year survival and less toxicity with IV CTX.

We aimed to compare risk of death, relapse, neutropenia and infection requiring hospital admission between unselected ANCA-associated vasculitis (AAV) patients according to whether cyclophosphamide induction was by daily oral (PO) or pulse intravenous (IV) route.

They studied 57 newly diagnosed AAV patients treated with PO or IV cyclophosphamide from 3/07 to 6/13 and compared death, relapse, neutropenia and hospitalized infections, after adjusting for age, renal function and other significant confounders.

One-year survival was greater with IV CTX (98.2% vs 86%) compared to PO (HR  PO vs IV = 1.8; 95% CI 0.3–10.6, P = 0.54).

One-year relapse-free survival was higher w/ IV CTX (87.3% vs 80.7% (HR 3.8; 95% CI 0.2–846, P = 0.37).

Toxicities were more likely with PO CTX (compared to IV) in the first 12 months.

  • neutropenia (16% PO and 0 IV) (P = 0.003).
  • hospitalized infections (28% PO  vs 16% IV) (OR 2.2; 0.6–8.6, P = 0.23).
  • there was a trend towards more deaths and admissions with PO cyclophosphamide.

Overall oral administration of CTX induces greater marrow toxicity and more infections.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Update on Immune Checkpoint Inhibitor Toxicity

JAMA has a 2018 update/review of the safety issues seen with mmune checkpoint inhibitors (ICIs) - important new cancer therapies, with 14 cancer indications, that have significantly improved survival in several. ICIs are monoclonal antibodies that block inhibitors of T-cell activation and function.

New BSR Guidelines on Biologic Safe Use with Inflammatory Arthritis

The British Society of Rheumatology has produced a set of NICE accredited guidelines for the use of biologic therapies in patients with inflammatory arthritis.

It addresses safety recommendations for all biologic therapies approved by the National Institute for Health and Care Excellence (NICE) up to June 2016, for use in all inflammatory arthritides [RA, PsA and axial SpA (SpA) including AS].

The Safety of Paternal Exposure to DMARDs and Biologics

Pregnancy and drug safety is a complex issue, often with limited informatoin about maternal drug exposure on the offspring. Greater uncertainty exists when considering whether paternal exposure may also influence fetal outcomes.

A systematic review examined the effect of disease modifying anti-rheumatic drugs (DMARDs) on male fertility and if peri-conception (within 3 months) paternal exposure was detrimental to fetal outcomes.

2018-2019 ACIP Recommendations for Seasonal Influenza Vaccination

The current issue of the CDC's MMWR reviews the new seasonal recommendations for vaccination against influenza. This is an update to the previous recommendations of the Advisory Committee on Immunization Practices (ACIP). 

Health Secretary Azar Eyes Rebate Reform

Reuters reports that the U.S. Health and Human Services Secretary Alex Azar had declared his agency has the authority to eliminate rebates on prescription drug purchases, a key element in the administration’s plan to lower prescription medicine costs.

Azar has said rebates created a perverse incentive to continuously raise drug prices.